First human test of lassa fever pill shows promise for safety
NCT ID NCT05735249
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental oral drug called ARN-75039, being developed to treat Lassa fever, a serious viral illness. The trial involved 94 healthy adults aged 18 to 55 who received either the drug or a placebo to check for side effects and how the drug moves through the body. The main goal was to see if the drug is safe and tolerable before testing it in people with Lassa fever.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Spaulding Clinical, LLC
West Bend, Wisconsin, 53095, United States